IMGN ImmunoGen, Inc.

-0.35  -7%
Previous Close 5.07
Open 5.05
Price To book 0.00
Market Cap 421.72M
Shares 89,348,000
Volume 2,413,289
Short Ratio 5.09
Av. Daily Volume 2,459,420

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b safety data at ASCO June 3, 2017. Abstract 5553.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 2 initiated 2016
IMGN529 and rituximab
Cancer - diffuse-large B-cell lymphoma (DLBCL)
Reported April 2016 that FORWARD I, initially a Phase 2 trial, will now be a Phase 3 trial with progression-free survival as the primary endpoint. Announced January 26, 2017 that first patient has been dosed.
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data due in 2019.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data due in 2018.
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer

Latest News

  1. ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference
  2. Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
  3. ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher
  4. Why ImmunoGen, Inc. Jumped Higher Today
  5. ImmunoGen drug moving ahead in single-agent, combination trials
  6. ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting
  7. Why ImmunoGen, Inc. Stock Is Flying High Today
  8. Edited Transcript of IMGN earnings conference call or presentation 5-May-17 12:00pm GMT
  9. ImmunoGen, Inc. Begins FORWARD I, Investors Wait
  10. ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1
  11. Today's Research Reports on Stocks to Watch: ImmunoGen and Ocular Therapeutix
  12. ImmunoGen (IMGN) Reports Narrower-than-Expected Loss
  13. Investor Network: ImmunoGen, Inc. to Host Earnings Call
  14. ImmunoGen reports 1Q loss
  15. ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results
  16. Why ImmunoGen (IMGN) Might Surprise This Earnings Season
  17. Here's Why ImmunoGen Rose 10.7% in April
  18. Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?
  19. ImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer
  20. When Will ImmunoGen, Inc. Finally Start Making Money?